Emicizumab
- Generic Name
- Emicizumab
- Brand Names
- Hemlibra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1610943-06-0
- Unique Ingredient Identifier
- 7NL2E3F6K3
- Background
Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous ...
- Indication
The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A with or without Factor VIII inhibitors.
...
- Associated Conditions
- Bleeding caused by Hemophilia A
- Associated Therapies
- -
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
- Conditions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06104826
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2023-03-01
- Target Recruit Count
- 40
- Registration Number
- NCT05500807
- Locations
- 🇺🇸
Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
Emicizumab in Patients With Acquired Hemophilia A
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 51
- Registration Number
- NCT05345197
- Locations
- 🇺🇸
Penn Blood Disorders Program, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸UCSD Hemophilia and Thrombosis Treatment Center, San Diego, California, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT05181618
- Locations
- 🇲🇦
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
🇮🇹IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi", Milano, Lombardia, Italy
🇭🇺Észak-Pesti Centrumkórház - Honvédkórház; Országos Hemofília Központ, Budapest, Hungary
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 120
- Registration Number
- NCT05022459
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT04690322
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Preventing Inhibitor Recurrence Indefinitely
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 52
- Registration Number
- NCT04621916
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
Hemlibra in Mild Hemophilia A
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04567511
- Locations
- 🇺🇸
Indiana Hemophila @Thrombosis Center, Indianapolis, Indiana, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT04431726
- Locations
- 🇦🇺
Perth Children's Hospital, Nedlands, Western Australia, Australia
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
The Hemophilia Inhibitor Eradication Trial
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Margaret Ragni
- Target Recruit Count
- 1
- Registration Number
- NCT04303572
- Locations
- 🇺🇸
University of Pittsburgh and Hemophilia Center Western PA, Pittsburgh, Pennsylvania, United States
🇺🇸Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.